このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

12歳以上の喘息患者を対象に、噴射剤HFA-152aまたはHFA-134aを含むMDIを介して投与されたサルブタモールによる3カ月間の治療の安全性と忍容性を評価および比較する研究

2026年9月11日 更新者:GlaxoSmithKline

噴射剤 HFA-152a または参照 HFA-134a を含む定量吸入器を介して投与された場合のサルブタモール救済薬の長期安全性を評価するための無作為化二重盲検並行グループ多施設研究

The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma

調査の概要

研究の種類

介入

入学 (実際)

471

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • North Hollywood、California、アメリカ、91606-3287
        • GSK Investigational Site
      • San Mateo、California、アメリカ、94403
        • GSK Investigational Site
    • Florida
      • Aventura、Florida、アメリカ、33180
        • GSK Investigational Site
      • Clearwater、Florida、アメリカ、33756
        • GSK Investigational Site
      • DeLand、Florida、アメリカ、32720
        • GSK Investigational Site
      • Miami、Florida、アメリカ、33173
        • GSK Investigational Site
      • Miami、Florida、アメリカ、33144
        • GSK Investigational Site
      • Miami、Florida、アメリカ、33155
        • GSK Investigational Site
      • Naples、Florida、アメリカ、34102
        • GSK Investigational Site
      • Plantation、Florida、アメリカ、33317
        • GSK Investigational Site
      • Winter Park、Florida、アメリカ、32789-3385
        • GSK Investigational Site
    • Georgia
      • Rincon、Georgia、アメリカ、31326-5131
        • GSK Investigational Site
      • Stonecrest、Georgia、アメリカ、30038
        • GSK Investigational Site
    • Kentucky
      • Louisville、Kentucky、アメリカ、40217
        • GSK Investigational Site
      • Owensboro、Kentucky、アメリカ、42301
        • GSK Investigational Site
    • Massachusetts
      • Fall River、Massachusetts、アメリカ、02723-1511
        • GSK Investigational Site
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55402-2508
        • GSK Investigational Site
      • Minneota、Minnesota、アメリカ、56001
        • GSK Investigational Site
    • Mississippi
      • Olive Branch、Mississippi、アメリカ、38654
        • GSK Investigational Site
    • Missouri
      • Columbia、Missouri、アメリカ、65203
        • GSK Investigational Site
    • Nevada
      • Henderson、Nevada、アメリカ、89052-5015
        • GSK Investigational Site
    • New Jersey
      • Jersey City、New Jersey、アメリカ、07306
        • GSK Investigational Site
      • Riverdale、New Jersey、アメリカ、07457
        • GSK Investigational Site
    • New York
      • Brooklyn、New York、アメリカ、11220
        • GSK Investigational Site
    • North Carolina
      • Asheville、North Carolina、アメリカ、28803
        • GSK Investigational Site
      • Winston-Salem、North Carolina、アメリカ、27104
        • GSK Investigational Site
    • Ohio
      • Cincinnati、Ohio、アメリカ、45231
        • GSK Investigational Site
      • Dublin、Ohio、アメリカ、43016
        • GSK Investigational Site
    • Oregon
      • Medford、Oregon、アメリカ、97504
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19107
        • GSK Investigational Site
      • Pittsburgh、Pennsylvania、アメリカ、15241
        • GSK Investigational Site
      • Pottstown、Pennsylvania、アメリカ、19464-3241
        • GSK Investigational Site
    • South Carolina
      • Rock Hill、South Carolina、アメリカ、29732
        • GSK Investigational Site
      • Spartanburg、South Carolina、アメリカ、29303
        • GSK Investigational Site
      • Spartanburg、South Carolina、アメリカ、29303-4225
        • GSK Investigational Site
      • Union、South Carolina、アメリカ、29379-7409
        • GSK Investigational Site
    • Texas
      • Sugar Land、Texas、アメリカ、77479
        • GSK Investigational Site
      • Tomball、Texas、アメリカ、77375-3332
        • GSK Investigational Site
      • Buenos Aires、アルゼンチン、C1425BEN
        • GSK Investigational Site
      • Buenos Aires、アルゼンチン、C1426ABP
        • GSK Investigational Site
      • Buenos Aires、アルゼンチン、C1425AZE
        • GSK Investigational Site
      • La Plata、アルゼンチン、1900
        • GSK Investigational Site
      • Mendoza、アルゼンチン、M5500CCG
        • GSK Investigational Site
      • Bebington、イギリス、CH63 9JP
        • GSK Investigational Site
      • Cambridgeshire、イギリス、CB7 5JD
        • GSK Investigational Site
      • Corby、イギリス、NN17 2UR
        • GSK Investigational Site
      • Greater Manchester、イギリス、OL6 6HD
        • GSK Investigational Site
      • Guisborough、イギリス、TS14 7DJ
        • GSK Investigational Site
      • Hounslow、イギリス、TW3 3EL
        • GSK Investigational Site
      • Rhyl、イギリス、LL18 4HZ
        • GSK Investigational Site
      • Uttoxeter、イギリス、ST14 5JX
        • GSK Investigational Site
      • Cagliari、イタリア、09042
        • GSK Investigational Site
      • Florence、イタリア、50134
        • GSK Investigational Site
      • Foggia、イタリア、71100
        • GSK Investigational Site
      • Milan、イタリア、20162
        • GSK Investigational Site
      • Naples、イタリア、80131
        • GSK Investigational Site
      • Padova、イタリア、35128
        • GSK Investigational Site
      • Torino、イタリア、10128
        • GSK Investigational Site
      • Tradate VA、イタリア、21100
        • GSK Investigational Site
      • Verona、イタリア、37134
        • GSK Investigational Site
    • RM
      • Roma、RM、イタリア、00161
        • GSK Investigational Site
    • New South Wales
      • Botany、New South Wales、オーストラリア、2019
        • GSK Investigational Site
      • Coffs Harbour、New South Wales、オーストラリア、2450
        • GSK Investigational Site
      • Kanwal、New South Wales、オーストラリア、2259
        • GSK Investigational Site
    • Western Australia
      • Spearwood、Western Australia、オーストラリア、6163
        • GSK Investigational Site
    • Ontario
      • Ajax、Ontario、カナダ、L1S 2J5
        • GSK Investigational Site
      • Brampton、Ontario、カナダ、L6T 0G1
        • GSK Investigational Site
      • Ottawa、Ontario、カナダ、K1H 1E4
        • GSK Investigational Site
      • Toronto、Ontario、カナダ、M9V 4B4
        • GSK Investigational Site
      • Windsor、Ontario、カナダ、N8X 2G1
        • GSK Investigational Site
    • Quebec
      • Québec、Quebec、カナダ、G1V 4W2
        • GSK Investigational Site
      • Québec、Quebec、カナダ、G1W 4R4
        • GSK Investigational Site
      • Athens、ギリシャ、15669
        • GSK Investigational Site
      • Larissa、ギリシャ、41110
        • GSK Investigational Site
      • Thessaloniki、ギリシャ、57010
        • GSK Investigational Site
      • Barcelona、スペイン、08017
        • GSK Investigational Site
      • Barcelona、スペイン、08540
        • GSK Investigational Site
      • Benalmádena、スペイン、29631
        • GSK Investigational Site
      • Madrid、スペイン、28041
        • GSK Investigational Site
      • Madrid、スペイン、28040
        • GSK Investigational Site
      • Madrid、スペイン、28031
        • GSK Investigational Site
      • Marbella、スペイン、29603
        • GSK Investigational Site
      • Pozuelo de AlarcOn Madr、スペイン、28223
        • GSK Investigational Site
      • Pathum Thani、タイ、12120
        • GSK Investigational Site
      • Panama City、パナマ
        • GSK Investigational Site
      • Panama City、パナマ、7099
        • GSK Investigational Site
      • Panama City、パナマ、7002
        • GSK Investigational Site
      • Iloilo City、フィリピン、5000
        • GSK Investigational Site
      • Amiens、フランス、80054
        • GSK Investigational Site
      • Argenteuil、フランス、95100
        • GSK Investigational Site
      • Créteil、フランス、94010
        • GSK Investigational Site
      • Poitiers、フランス、86021
        • GSK Investigational Site
      • Pontoise、フランス、95303
        • GSK Investigational Site
      • Strasbourg、フランス、67091
        • GSK Investigational Site
      • Bialystok、ポーランド、15-010
        • GSK Investigational Site
      • Bielsko-Biala、ポーランド、43-300
        • GSK Investigational Site
      • Chorzów、ポーランド、41-500
        • GSK Investigational Site
      • Elblag、ポーランド、82-300
        • GSK Investigational Site
      • Katowice、ポーランド、40-600
        • GSK Investigational Site
      • Ostrowiec Świętokrzyski、ポーランド、27-400
        • GSK Investigational Site
      • Płock、ポーランド、09-407
        • GSK Investigational Site
      • Tarnów、ポーランド、33-100
        • GSK Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.

  2. Asthma for ≥ 6 months, defined as:

    • Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]

    • Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:

      • Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
      • Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
      • Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
      • Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
      • Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
  3. Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)

  4. Asthma Control Status

    • Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening

    • Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:

      • Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
      • An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
  5. Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.

  6. Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):

    • With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.

    • Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.

      • SABA should be withheld for ≥6 hours
      • Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
  7. Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:

    • Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.

      • SABA should be withheld for ≥6 hours
      • LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.

Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.

Exclusion Criteria:

  1. A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
  2. Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
  3. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
  4. Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
  5. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Salbutamol HFA-152a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 μg (ex-valve) at 30-second intervals per actuation

アクティブコンパレータ:Salbutamol HFA-134a MDI

Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13.

100 microgram (μg) (ex-valve) at 30-second intervals per actuation

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Adverse Events (AEs) During Run-in Period
時間枠:From Week -1 up to randomization (Day 1) during Run-in period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Adverse Events (AEs) During Treatment Period
時間枠:From randomization (Day 1) up to Week 13 (Follow up) during treatment period

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
時間枠:From Week -1 up to randomization (Day 1) during Run-in period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
時間枠:From randomization (Day 1) up to Week 13 (Follow up) during treatment period

SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Absolute Values of Minimum Serum Potassium
時間枠:Up to Week 13 (Follow up)

Blood samples were collected to analyze minimum serum potassium.

Up to Week 13 (Follow up)
Absolute Values of Serum Potassium at Each Assessed Visit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Erythrocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Erythrocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCV
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCH
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hematocrit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hematocrit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Specific Gravity
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Specific Gravity
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
時間枠:Up to Week 13 (Follow up)

Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result.

Up to Week 13 (Follow up)
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Vital Signs: Pulse Rate
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Pulse Rate
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13

Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline for 12 Lead ECGs in QTcF
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Heart Rate
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Heart Rate
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13

A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
時間枠:Baseline (Day 1, pre-dose) and Week 12

The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
時間枠:Baseline (Day 1, pre-dose) and Week 12

Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.

Baseline (Day 1, pre-dose) and Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:GSK Clinical Trials、GlaxoSmithKline

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年5月31日

一次修了 (実際)

2025年9月2日

研究の完了 (実際)

2025年9月2日

試験登録日

最初に提出

2024年2月8日

QC基準を満たした最初の提出物

2024年2月8日

最初の投稿 (実際)

2024年2月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年9月11日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 220735
  • 2023-509001-76-00 (その他の識別子:EU CT Number)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD 共有時間枠

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD 共有アクセス基準

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する